XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Astellas Agreement [Member] | Japan [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration $ 117,447  
Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 17,100  
Astellas Agreement [Member] | Japan [Member] | License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 100,347  
Astellas Agreement [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 906,297  
Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 287,322  
Astellas Agreement [Member] | Europe [Member] | License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 618,975  
AstraZeneca Agreements [Member]    
Disaggregation of Revenue [Line Items]    
Deferred Revenue 158,593 $ 179,851
AstraZeneca Agreements [Member] | China performance obligation [Member]    
Disaggregation of Revenue [Line Items]    
Deferred Revenue 158,600  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 344,500  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 625,500  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration $ 427,500